Search and analyze individual stocks with comprehensive metrics
Syngene International Ltd
Fundamental Score
Syngene International Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SYNGENE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (29.64%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (12.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (12.45x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹1615.90 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 40.93%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 55.50x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-36.76%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Loading Peer Comparison
Finding companies in the Healthcare Research, Analytics & Technology sector...
Financial Statements
Comprehensive financial data for Syngene International Ltd
About SYNGENE
Business Overview
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Company Details
Key Leadership
Corporate Events
Latest News
SYNGENE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Syngene International Ltd (SYNGENE)?
As of 15 Jan 2026, 05:10 am IST, Syngene International Ltd (SYNGENE) is currently trading at ₹631.85. The stock has a market capitalization of ₹25.99K (Cr).
Is SYNGENE share price Overvalued or Undervalued?
SYNGENE is currently trading at a P/E ratio of 55.50x, compared to the industry average of 45.95x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Syngene International Ltd share price?
Key factors influencing SYNGENE's price include its quarterly earnings growth (Sales Growth: 2.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Syngene International Ltd a good stock for long-term investment?
Syngene International Ltd shows a 5-year Profit Growth of 5.71% and an ROE of 10.53%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.12 before investing.
How does Syngene International Ltd compare with its industry peers?
Syngene International Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare SYNGENE's P/E of 55.50x and ROE of 10.53% against the industry averages to determine its competitive standing.
What is the P/E ratio of SYNGENE and what does it mean?
SYNGENE has a P/E ratio of 55.50x compared to the industry average of 45.95x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹56 for every ₹1 of annual earnings.
How is SYNGENE performing according to Bull Run's analysis?
SYNGENE has a Bull Run fundamental score of 41.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SYNGENE belong to?
SYNGENE operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Syngene International Ltd.
What is Return on Equity (ROE) and why is it important for SYNGENE?
SYNGENE has an ROE of 10.53%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Syngene International Ltd generates profits from shareholders' equity.
How is SYNGENE's debt-to-equity ratio and what does it indicate?
SYNGENE has a debt-to-equity ratio of 0.12, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SYNGENE's dividend yield and is it a good dividend stock?
SYNGENE offers a dividend yield of 0.19%, which means you receive ₹0.19 annual dividend for every ₹100 invested.
How has SYNGENE grown over the past 5 years?
SYNGENE has achieved 5-year growth rates of: Sales Growth 12.60%, Profit Growth 5.71%, and EPS Growth 5.58%.
What is the promoter holding in SYNGENE and why does it matter?
Promoters hold 52.68% of SYNGENE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SYNGENE's market capitalization category?
SYNGENE has a market capitalization of ₹25986 crores, placing it in the Large-cap category.
How volatile is SYNGENE stock?
SYNGENE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SYNGENE?
SYNGENE has a 52-week high of ₹N/A and low of ₹N/A.
What is SYNGENE's operating profit margin trend?
SYNGENE has a 5-year average Operating Profit Margin (OPM) of 29.64%, indicating the company's operational efficiency.
How is SYNGENE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 2.20% and YoY Profit Growth of -36.76%.
What is the institutional holding pattern in SYNGENE?
SYNGENE has FII holding of 16.31% and DII holding of 24.62%. Significant institutional holding often suggests professional confidence in the stock.